70. Motzer RJ et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
N Engl J Med 356(2):115–124
71. Carducci MA et al (2015) Atrasentan in patients with advanced renal cell carcinoma: a phase
2 trial of the ECOG-ACRIN Cancer Research Group (E6800). Clin Genitourin Cancer 13
(6):531–539.e1
72. Bhargava P, Robinson MO (2011) Development of second-generation VEGFR tyrosine kinase
inhibitors: current status. Curr Oncol Rep 13(2):103–111
73. Raymond E et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine
tumors. N Engl J Med 364(6):501–513
74. Llovet JM et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359
(4):378–390
75. Grothey A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal
cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase
3 trial. Lancet 381(9863):303–312
76. Demetri GD et al (2013) Efficacy and safety of regorafenib for advanced gastrointestinal
stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre,
randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):295–302
77. Bruix J et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on
sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase
3 trial. Lancet 389(10064):56–66
78. Zirlik K, Duyster J (2018) Anti-angiogenics: current situation and future perspectives. Oncol
Res Treat 41(4):166–171
79. Srinivasan D, Plattner R (2006) Activation of Abl tyrosine kinases promotes invasion of
aggressive breast cancer cells. Cancer Res 66(11):5648–5655
80. Sirvent A et al (2007) The tyrosine kinase Abl is required for Src-transforming activity in
mouse fibroblasts and human breast cancer cells. Oncogene 26:7313
81. Mgbemena VE (2014) Re-evaluating the role of BCR/ABL in chronic myelogenous leukemia
AU – Ross, Theodora S. Mol Cell Oncol 1(3):e963450
82. Schenone S et al (2015) Analogs, formulations and derivatives of imatinib: a patent review
AU – Musumeci, Francesca. Expert Opin Ther Pat 25(12):1411–1421
83. Cohen MH et al (2002) Approval summary for imatinib mesylate capsules in the treatment of
chronic myelogenous leukemia. Clin Cancer Res 8(5):935–942
84. Dematteo RP et al (2009) Adjuvant imatinib mesylate after resection of localised, primary
gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet
373(9669):1097–1104
85. Dagher R et al (2002) Approval summary. Imatinib mesylate in the treatment of metastatic
and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8
(10):3034–3038
86. Hasford J et al (2011) Predicting complete cytogenetic response and subsequent progressionfree survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 118
(3):686–692
87. Hochhaus A et al (2002) Molecular and chromosomal mechanisms of resistance to imatinib
(STI571) therapy. Leukemia 16:2190
88. Rossari F, Minutolo F, Orciuolo E (2018) Past, present, and future of Bcr-Abl inhibitors: from
chemical development to clinical efficacy. J Hematol Oncol 11(1):84–84
89. Kantarjian HM et al (2011) Nilotinib versus imatinib for the treatment of patients with newly
diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia:
24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 12
(9):841–851
90. Kantarjian HM et al (2012) Dasatinib or imatinib in newly diagnosed chronic-phase chronic
myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 119
(5):1123–1129
148
A. Moschopoulou et al.
N Engl J Med 356(2):115–124
71. Carducci MA et al (2015) Atrasentan in patients with advanced renal cell carcinoma: a phase
2 trial of the ECOG-ACRIN Cancer Research Group (E6800). Clin Genitourin Cancer 13
(6):531–539.e1
72. Bhargava P, Robinson MO (2011) Development of second-generation VEGFR tyrosine kinase
inhibitors: current status. Curr Oncol Rep 13(2):103–111
73. Raymond E et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine
tumors. N Engl J Med 364(6):501–513
74. Llovet JM et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359
(4):378–390
75. Grothey A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal
cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase
3 trial. Lancet 381(9863):303–312
76. Demetri GD et al (2013) Efficacy and safety of regorafenib for advanced gastrointestinal
stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre,
randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):295–302
77. Bruix J et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on
sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase
3 trial. Lancet 389(10064):56–66
78. Zirlik K, Duyster J (2018) Anti-angiogenics: current situation and future perspectives. Oncol
Res Treat 41(4):166–171
79. Srinivasan D, Plattner R (2006) Activation of Abl tyrosine kinases promotes invasion of
aggressive breast cancer cells. Cancer Res 66(11):5648–5655
80. Sirvent A et al (2007) The tyrosine kinase Abl is required for Src-transforming activity in
mouse fibroblasts and human breast cancer cells. Oncogene 26:7313
81. Mgbemena VE (2014) Re-evaluating the role of BCR/ABL in chronic myelogenous leukemia
AU – Ross, Theodora S. Mol Cell Oncol 1(3):e963450
82. Schenone S et al (2015) Analogs, formulations and derivatives of imatinib: a patent review
AU – Musumeci, Francesca. Expert Opin Ther Pat 25(12):1411–1421
83. Cohen MH et al (2002) Approval summary for imatinib mesylate capsules in the treatment of
chronic myelogenous leukemia. Clin Cancer Res 8(5):935–942
84. Dematteo RP et al (2009) Adjuvant imatinib mesylate after resection of localised, primary
gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet
373(9669):1097–1104
85. Dagher R et al (2002) Approval summary. Imatinib mesylate in the treatment of metastatic
and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8
(10):3034–3038
86. Hasford J et al (2011) Predicting complete cytogenetic response and subsequent progressionfree survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 118
(3):686–692
87. Hochhaus A et al (2002) Molecular and chromosomal mechanisms of resistance to imatinib
(STI571) therapy. Leukemia 16:2190
88. Rossari F, Minutolo F, Orciuolo E (2018) Past, present, and future of Bcr-Abl inhibitors: from
chemical development to clinical efficacy. J Hematol Oncol 11(1):84–84
89. Kantarjian HM et al (2011) Nilotinib versus imatinib for the treatment of patients with newly
diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia:
24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 12
(9):841–851
90. Kantarjian HM et al (2012) Dasatinib or imatinib in newly diagnosed chronic-phase chronic
myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 119
(5):1123–1129
148
A. Moschopoulou et al.